Kisplyx -Keytruda Continues to Show Benefit in Advanced Kidney Cancer
The drug duo Kisplyx plus Keytruda led to improved outcomes for patients with advanced renal cell carcinoma, ...
News Archive
Kidney Cancer News
Adding Cabometyx to Immunotherapy Improves Kidney Cancer Outcomes
The addition of Cabometyx to Opdivo and Yervoy improved outcomes for patients with advanced kidney cancer, ...
Our Kidney Cancer Patient Survey 2022 Report
Kidney cancer guidelines for doctors needed now
In the week of Kidney Cancer Awareness Week 2023, Kidney ...
Kidney Cancer UK secure landmark kidney cancer NICE clinical guideline
Kidney Cancer UK, the UK’s leading kidney cancer charity has, through its approach to NHS England, secured a ...
NHS gives GP teams direct access to tests to speed up cancer diagnosis
NHS Press Release (16th November 2022)
Tens of thousands of cancers could be detected sooner each year thanks to ...
Pembrolizumab recommended as an adjuvant therapy for RCC across UK
The Scottish Medical Consortium have recommended Pembrolizumab (Keytruda) as a monotherapy which is indicated for ...
Highlights from the ESMO Congress 2022
We are delighted to share with you the report from The European Society of Medical Oncology (ESMO) congress 2022 ...
The Challenges and Opportunities for Kidney Cancer Care Recovery report
In anticipation of the Government’s upcoming 10-year Cancer Plan, Kidney Cancer UK is pleased to welcome the publication of the report – ‘The Challenges and Opportunities for Kidney Cancer Care Recovery’.
Opdivo + Yervoy fails adjuvant phase 3 trial
Bristol-Myers Squibb has revealed that its checkpoint inhibitor combination of Opdivo and Yervoy failed a phase 3 ...
New Approach to Treating VHL RCC
The research could be used to develop more targeted kidney cancer drugs.
Researchers from Sweden’s Karolinska ...
Savolitinib not significantly efficacious in aRCC
Savolitinib, alone or in combination with durvalumab, did not demonstrate significant efficacy in patients with ...
Cabo + nivo & ipi delays kidney cancer progression
Adding cabozantinib (Cabometyx) to nivolumab (Opdivo) and ipilimumab (Yervoy) improved progression-free survival ...
No results found.